Mammary tumor growth and metastasis are reduced in c-Kit mutant Sash mice

Licai He¹, Zhenfeng Zhu¹, Shang Chen¹, Yongping Wang² & Haihua Gu¹²

¹Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325035, China
²Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045

Keywords
Breast cancer, mast cells, metastasis, mouse models, tumor growth

Abstract
Besides its well-known function in allergic response, mast cell, one of the key immune cells present in tumor microenvironment, plays important roles in cancer progression. However, the functional role of mast cells in breast cancer development and metastasis is not well understood. To test the involvement of mast cells in breast cancer, we examined the effects of loss of mast cells on mammary tumor development by crossing the well-known mast cell deficient mouse strain sash (Kit\textsuperscript{W-sh/W-sh}) with the mammary tumor transgenic mouse strain MMTV-Polyoma Middle T antigen (PyMT). Although mammary tumor onset was not affected in the absence of mast cells, mammary growth and metastasis were reduced in PyMT/Kit\textsuperscript{W-sh/W-sh} mice compared with PyMT/wild-type mice (WT). Histological and immunofluorescent analyses showed that tumors from PyMT/Kit\textsuperscript{W-sh/W-sh} mice showed largely differentiated morphology with reduced angiogenesis compared with MMTV-PyMT/WT mice. Our results suggest that mast cells may promote breast cancer growth and metastasis. Agents that can block mast cells growth are potential new therapies to treat metastatic breast cancer.

Introduction
Mast cells are originated from progenitors in bone marrow, travel through the blood, and become differentiated into mature mast cells in various tissues. They are primarily known for their role in allergic responses [1]. However, in the last 15 years, studies mainly using mouse models for various types of cancers, including squamous carcinoma [2], neurofibromatosis [3, 4], and pancreatic islet tumor [5], reveal the tumor-promoting role of mast cells in different cancers. Meanwhile, the suppressive function of mast cells in cancer was implicated in a few studies, including in intestinal tumorigenesis [6]. Most of these studies used mutant mice strains that are deficient in mast cells. These mutant mice include the Kit\textsuperscript{W/Wv} [7] and Sash (Kit\textsuperscript{W-sh/W-sh}) strains [8], which have mutations in the coding regions that impair the kinase activity of c-Kit, and in the 5’ untranslated region that inhibits c-Kit expression, respectively. The main function of mast cells in tumor stroma is to stimulate the tumor cell growth directly or indirectly by promoting tumor growth and angiogenesis through secreting factors and proteases during the premalignant stage.

The roles of mast cells in breast cancer have been controversial. Mast cells are found in the stroma of human mammary carcinoma [9, 10]. However, the results from various studies examining the association of mast cells with disease outcome are conflicting. It has been reported that the presence of higher number of mast cells in breast tumor stroma is correlated with good prognosis of the
patients [11, 12]. Another study has shown higher mast cell number in sentinel lymph node is correlated with increased angiogenesis and micrometastases in patients with breast cancer [13]. Thus, it is not clear whether mast cells play a positive or negative role during breast cancer progression and metastasis.

To clarify the role of mast cells in mammary tumor development and metastasis, we examined the effects of loss of mast cells on mammary tumor progression by crossing the mast cell deficient mice KitW-sh/W-sh with the MMTV-Polyoma Middlet T antigen (PyMT) mice, which is a well-known transgenic mouse model of breast cancer that develops pulmonary metastasis [14]. We found that mammary growth and metastasis are reduced in PyMT/KitW-sh/W-sh mice compared with PyMT mice, suggesting that mast cells play a positive role in mammary development and metastasis.

**Materials and Methods**

**Mice and genotyping**

MMTV-PyMT (PyMT) mice, originally generated by Bill Muller’s lab [14], in C57BL/6 background were kindly provided by Dr. Sandra Gendler (Mayo Clinic, Arizona). Sash (KitW-sh/W-sh) mice in C57BL/6 were purchased from The Jackson Laboratory (Bar Harbor, ME). Male PyMT mice were mated with female KitW-sh/W-sh mice to generate progenies with the genotype of Kit+/W-sh or PyMT (PyMT+/−)/Kit+/W-sh. Female Kit+/W-sh and male PyMT/Kit+/W-sh mice were mated against each other to generate female littersmates that are PyMT/wild-type (WT) and PyMT/KitW-sh/W-sh. Mice were genotyped for the PyMT allele by polymerase chain reaction (PCR) using the following primers: forward primer, AGTCAGTCTACTGACCCAG, and reverse primer, CTCTCTCATCGTCTTGAGCTCC as described [15]. Sash mutant mice were genotyped based on the coat color that shows mice with black fur with white sash at the midline (The Jackson Laboratory). Protocols for all mouse experiments were approved by the Institutional Animal Care and Use Committee at the University of Colorado Anschutz Medical Campus and Wenzhou Medical University.

**Monitoring mammary tumor development**

At 60 days of age, mice were palpated every week to detect the onset of mammary tumor development. After the detection of palpable tumors, mice were monitored for tumor growth with caliper every 2 weeks. Total tumor volume was determined using the formula: volume = (L*W²)/2. Mice were killed at 8 weeks or 10 weeks after the onset of tumors.

**Quantitation of lung metastasis**

Lung tissues were dissected from mice, flash frozen in liquid nitrogen, and stored at −80°C. Total RNAs (1 μg) isolated from lungs using Trizol Reagent (Invitrogen, Carlsbad, CA) and tissue homogenizer (Kinematica Inc, Bohemia, NY) were treated with DNaseI and reverse transcribed into cDNA using Superscript III (Invitrogen). Quantitative Reverse Transcription (RT)-PCR was performed on 7500 fast real-time PCR systems (Applied Biosystems, Foster City, CA) using Power SYBR Green PCR Master Mix (Applied Biosystems). PCR primers were: PyMT gene, forward primer, AGGCCGATGACACCATATCC, and reverse primer, GTACTGAGTGTCGCCCTTCAGGAT; mouse GAPDH gene, forward primer, AGGTTCAGGAGGATGTCG; reverse primer: TTAGAGCCAGTGAGGGT. Relative PyMT mRNA level normalized to GAPDH mRNA level represents the relative lung metastasis of the PyMT mammary tumors.

**Histology and immunohistochemistry analyses**

Tumor and lung tissues were fixed in 10% formalin or Bouin’s solution for 24 h, and embedded in paraffin. Sections were stained with Hematoxylin and Eosin (H&E) or toluidine blue to visualize mast cells as described [16]. For immunohistochemistry (IHC), paraffin sections were deparaffinized, and antigens were heat retrieved in 10 mmol/L citrate buffer pH 6.0 in microwave. Anti-CD31/PECAM1 rabbit antibodies were purchased from Santa Cruz Biotechnology (SC-1306). Envision+ anti-rabbit horseradish peroxidase system (Dako, Carpinteria, CA) was used for antibody detection. CD31-stained images were captured under the 10X objective lens using the Nikon Eclipse Ti-S/L 100 microscope system. Images of six random fields for each tumor were taken as TIF files. The optical intensity of CD31 IHC staining in each field was analyzed and normalized to the area size of the chosen field using image-pro plus software.

**Statistical analysis**

Survival curves were generated using the Kaplan–Meier method, and significance was evaluated using the log-rank test. Paired data were evaluated by unpaired two-tailed Student’s t test.

**Results**

To explore the function of mast cells during mammary tumor progression, we examined the effects of loss of mast cells on mammary tumor development by crossing the mast
cell deficient mice sash (KitW-sh/W-sh) (C57BL/6 background) with the MMTV-PyMT mice (C57BL/6). KitW-sh/W-sh mice have a DNA inversion mutation in the 5′ upstream regulatory region of the c-Kit gene that results in impaired c-Kit expression and mast cell development in tissues [8]. Compared to the widely used mast cell deficient mice strains such as KitW/Wv, KitW-sh/W-sh mice are fertile and without anemia, and have pretty normal development of other hematopoietic lineages such as lymphocytes and macrophages [8]. Tumor development in MMTV-PyMT (PyMT) mice follows a progression path including hyperplasia, adenoma, early carcinoma and late carcinoma, which is very similar to progressions seen in human breast cancers [17]. PyMT mice in the C57BL/6 background develop palpable breast tumors around 90 days of age [15], which is slower than mice in the FvB background [14].

According to the breeding strategy illustrated in Figure 1A, we generated female control PyMT/WT and littermate PyMT/KitW-sh/W-sh mice. Mice with both genotypes developed palpable mammary tumors between 60 and 150 days of age (Fig. 1B). Mammary tumor onset of PyMT/KitW-sh/W-sh mice is not significantly different from that of the control PyMT/WT mice. This result indicates that mast cells are not required for the induction of mammary tumors. Upon detection of tumor onset, four PyMT/WT and four littermate PyMT/KitW-sh/W-sh mice were monitored for tumor growth biweekly for 10 weeks.

The growth rate of the PyMT/KitW-sh/W-sh tumor is about 50–60% of PyMT/WT tumors (Fig. 1C).

Ten weeks after the detection of palpable tumors, the mice were euthanized and lung tissues were dissected out for examination of metastasis. Lung metastasis foci were visually seen in PyMT/WT mice. In contrast, lung metastasis foci were significantly reduced both in size and number in PyMT/KitW-sh/W-sh mice (Fig. 2A and B). Quantitation of lung metastasis by measuring the relative amounts of PyMT mRNA present in the lungs showed that the lung metastasis was reduced by more than 50% in PyMT/KitW-sh/W-sh mice compared with PyMT/WT mice (Fig. 2C).

The presence of mast cells in mammary tumors from PyMT/WT and PyMT/KitW-sh/W-sh mice were examined by toluidine blue staining. Mast cells were found around the edge of mammary tumors in PyMT/WT mice but not inside the mass of mammary tumor cells (Fig. 3A). As expected, no mast cells were detected in any parts of the mammary tumors from PyMT/KitW-sh/W-sh mice (data not shown). These results strongly suggest that mast cells play a positive role in breast cancer progression.

The histology of the mammary tumors was examined by H&E staining from mice killed 10 weeks after the onset of tumor. Tumors in PyMT/WT mice were mainly poorly differentiated and with solid sheets of malignant cells (Fig. 3B left). In contrast, large portion of the tumors in PyMT/KitW-sh/W-sh mice showed well-differentiated properties (i.e., the presence of the basement membranes with luminal space) (Fig. 3B right).

Because mast cells promote tumor growth via increased angiogenesis in several mouse tumor models (30, 31), tumor angiogenesis was also examined in tumor sections by immunohistochemistry with the anti-CD31 antibodies that stain endothelial cells in blood vessels. We found that there was ~70% decrease in the density of
CD31-stained blood vessels in PyMT/KitW-sh/W-sh tumors compared with that in PyMT/WT tumors (Fig. 3C and D). These results suggest that mast cells may be important for angiogenesis of mammary tumors.

### Discussion

Our study is the first one that applies the widely used mast cell deficient mouse strain. Sash (KitW-sh/W-sh) to test the role of mast cells in mammary tumor development. The results of our study suggest that mast cells play positive roles in the growth and metastasis of breast cancer.

Published studies imply that mast cells promote metastasis of breast cancer. Our study provides the functional data to support the important role of mast cells in metastasis of mammary tumors. Examining mast cells in human breast tumor samples showed that higher mast cell number in sentinel lymph node is correlated with increased angiogenesis and micrometastases in patients with breast cancer [13]. A recent study revealed that arthritis promotes mammary tumor metastasis to lung through mast cells in the MMTV-PyMT mouse model [18]. Treating mice with an antibody against c-Kit reduced mast cells and lung metastasis in this arthritis model [18]. Our observations that reduced lung metastasis and tumor angiogenesis in PyMT/KitW-sh/W-sh mice are consistent with these published results. Because mast cells are mainly present at the peripheral sites of breast tumors [9] (Fig. 3A), it is very possible that mast cells secrete factors or proteases that help breast cancer cells break away from their primary site.

The result of our study is also inconsistent with the conclusions from several published reports. Some published literatures revealed breast cancer with high levels of mast cells present in tumor stroma is associated with better outcome [9, 10]. Gene expression study has shown that MMTV-PyMT mammary tumor model resembles luminal breast cancer more closely [19]. It is possible that mast cells may have different functions in the luminal (ER+) breast cancer compared with Her2+ and triple negative breast cancer. Alternatively, mast cells may have different functions at earlier and later stages of breast cancer development. Data in our model strongly suggest that the early presence of stromal mast cells promotes mammary tumor growth and metastasis. However, in human breast cancer, the presence of higher numbers of mast cells in the fully developed breast tumors may impede breast cancer progression.

Our result indicates that mast cells do not affect mammary tumor onset. Interestingly, the result from an animal study using the Ws/Ws rats, deficient in mast cells in vivo, in response to N-nitroso methylurea (NMU) treatment seems to suggest that mast cells inhibit the onset of mammary tumors induced by NMU [20]. In the Ws/Ws rat study, rats are from mixed background of Brown Norway and Donryu strains, and the control WT rats are not littermates, which may contribute to their different sensitivity to NMU induced mammary tumorigenesis. In contrast, mice are
In addition, mammary tumor growth and metastasis were not examined in the Ws/Ws rat study [20]. Published studies, together with our data, suggest that mast cells may promote tumor angiogenesis that is important for mammary tumor metastasis. Our study showed that there was reduced tumor angiogenesis in PyMT/KitW-sh/W-sh mice compared with PyMT/WT mice (Fig. 3C). In the MMTV-PyMT model, it has been demonstrated elegantly that inhibition of the angiogenic switch [21], due to the loss of macrophages-derived angiogenic factor VEGF [22], blocks lung metastasis of mammary tumors. Studies from the squamous carcinoma mouse model indicate that mast cells-derived matrix metalloprotease 9 (MMP9) is important for the production of mature VEGF in the tumor microenvironment [23]. Future studies are required to ascertain whether mast cells regulate the production of MMPs or some factors to promote mammary tumor angiogenesis and metastasis in our model. In addition, future experiment involving reconstitution of KitW-sh/W-sh mice with WT mast cells should also help exclude whether other types of hematopoietic cells contribute to the phenotypes that we described in our model.

In conclusion, data from our study using mouse models provide strong functional evidence to support a positive role of mast cells in breast cancer growth and metastasis. Drugs or agents that can inhibit the growth of mast cells may be useful to treat patients with metastatic breast cancer in the future.

Acknowledgments

This work was supported in part by grants from National Natural Science Foundation of China (81372826 and 81400125), Natural Science Foundation of Zhejiang Province, China (LQ13H080002), and startup funds from Wenzhou Medical University and Pathology Department at the University of Colorado Denver.
Conflict of Interest

None declared.

References

1. Wedemeyer, J., M. Tsai, and S. J. Galli. 2000. Roles of mast cells and basophils in innate and acquired immunity. Curr. Opin. Immunol. 12:624–631.

2. Coussens, L. M., W. W. Raymond, G. Bergers, M. Laig-Webster, O. Behrendtzen, Z. Werb, et al. 1999. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13:1382–1397.

3. Zhu, Y., P. Ghosh, P. Charnay, D. K. Burns, and L. F. Parada. 2002. Neurofibromas in NF1: schwann cell origin and role of tumor environment. Science 296:920–922.

4. Yang, F. C., D. A. Ingram, S. Chen, C. M. Hingtgen, N. Ratner, K. R. Monk, et al. 2003. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for NF1−/− mast cells. J. Clin. Invest. 112:1851–1861.

5. Soucek, L., E. R. Lawlor, D. Soto, K. Shchors, L. B. Swigart, and G. I. Evan. 2007. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13:1211–1218.

6. Sinnamon, M. J., K. J. Carter, L. P. Sims, B. Lafleur, B. Fingleton, and L. M. Matrisian. 2008. A protective role for mast cells in intestinal tumorigenesis. Carcinogenesis 29:880–886.

7. Galli, S. J., M. Tsai, J. R. Gordon, E. N. Geissler, and B. K. Wershil. 1992. Analyzing mast cell development and function using mice carrying mutations at W/c-kit or Sl/MGF (SCF) loci. Ann. N.Y. Acad. Sci. 664:69–88.

8. Grimbaldeston, M. A., C. C. Chen, A. M. Piliponsky, M. Tsai, S. Y. Tam, and S. J. Galli. 2005. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am. J. Pathol. 167:835–848.

9. Kankkunen, J. P., I. T. Harvima, and A. Naukkarinen. 1997. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int. J. Cancer 72:385–388.

10. Marichal, T., M. Tsai, and S. J. Galli. 2013. Mast cells: potential positive and negative roles in tumor biology. Cancer Immunol. Res. 1:269–279.

11. Aaltomaa, S., P. Lipponen, S. Papinaho, and V. M. Kosma. 1993. Mast cells in breast cancer. Anticancer Res. 13:785–788.

12. Rajput, A. B., D. A. Turbin, M. C. Cheang, D. K. Voduc, S. Leung, K. A. Gelmon, et al. 2008. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res. Treat. 107:249–257.

13. Ribatti, D., N. Finato, E. Crivellato, D. Guidolin, V. Longo, D. Mangieri, et al. 2007. Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases. Histopathology 51:837–842.

14. Guy, C. T., R. D. Cardiff, and W. J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954–961.

15. Spicer, A. P., G. J. Rowe, T. K. Lidner, and S. J. Gendler. 1995. Delayed mammary tumor progression in Muc-1 null mice. J. Biol. Chem. 270:30093–30101.

16. Yu, M., J. Luo, W. Yang, Y. Wang, M. Mizuki, Y. Kanakura, et al. 2006. The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J. Biol. Chem. 281:28615–28626.

17. Lin, E. Y., J. G. Jones, P. Li, L. Zhu, K. D. Whitney, W. J. Muller, et al. 2003. Progression to malignancy in the polyoma middle T oncprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163:2113–2126.

18. Das Roy, L., J. M. Curry, M. Sahraei, D. M. Besmer, A. Kidiyoor, H. E. Gruber, et al. 2013. Arthritis augments breast cancer metastatic role of mast cells and SCF/c-Kit signaling. Breast Cancer Res. 15:R32.

19. Hollern, D. P., and E. R. Andrecheek. 2014. A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer. Breast Cancer Res. 16:R59.

20. Maffini, M. V., A. M. Soto, C. Sonnenschein, N. Papadopoulos, and T. C. Theoharides. 2008. Lack of c-receptor promotes mammary tumors in N-nitrosomethylurea-treated Ws/Ws rats. Cancer Cell Int. 8:5.

21. Lin, E. Y., J. F. Li, L. Gnatovskiy, Y. Deng, L. Zhu, D. A. Grzesik, et al. 2006. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66:11238–11246.

22. Lin, E. Y., J. F. Li, G. Bricard, W. Wang, Y. Deng, R. Sellers, et al. 2007. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol. Oncol. 1:288–302.

23. Coussens, L. M., C. L. Tinkle, D. Hanahan, and Z. Werb. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481–490.